$OSUR

OraSure (OSUR) reported Q2 2026 GAAP net income of $6.2M, reversing a $19.7M loss from a year earlier. Revenue rose 9.7% quarter-over-quarter to $30.6M, beating guidance. Gross margins improved, and diagnostics revenue grew 1% YoY. The profit was largely due to a $22.6M accounting adjustment, with underlying losses widening. The company secured two FDA clearances but delayed a product submission. Hedge fund ownership increased, and short interest is 4.79%.

OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.

ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nasdaq: OSUR), a leader in point-of-need and home diagnost

OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.

OraSure (NASDAQ: OSUR) said the FDA has cleared its Colli-Pee at-home urine collection kit, made by subsidiary DNA Genotek, for use with Roche molecular diagnostic systems to identify multiple STIs. OraSure called the clearance important for future growth and noted it also filed for a rapid molecular self-test for Chlamydia and gonorrhoeae. Shares were up over 2% to $4.14.

OraSure Technologies said the FDA cleared its Colli-Pee™•Dx urine collection kit (from subsidiary DNA Genotek) for at-home first-void urine collection for Roche cobas 5800/6800/8800 molecular testing. The kit supports tests for Chlamydia, Gonorrhea, Trichomonas vaginalis, and Mycoplasma genitalium, enabling mail-in workflows and decentralized STI screening.

Peapod Lane Capital LLC significantly increased its stake in OraSure Technologies, making it their 17th-largest holding. Meanwhile, insider activity shows the CEO and CFO recently purchased shares, indicating confidence in the company. Despite this, OraSure Technologies is currently trading near $3.05 with a "Reduce" analyst consensus and a target price of $3.00, having reported negative EPS and margins last quarter.

OraSure Technologies' shares jumped by as much as 15% after the Centers for Medicare and Medicaid Services (CMS) proposed covering hepatitis-C tests for select high-risk patients. OraSure develops a rapid diagnostic test for HCV, making this potential policy change significant for the company's future revenue. If adopted, the proposal could boost OraSure's financial performance and encourage more baby boomers to get tested.

OraSure Technologies is defending its performance and governance against activist investor Altai Capital's challenge, asserting that its shareholder returns have met or exceeded those of its peers. The company highlights its focused growth strategy, new diagnostic products, cost-cutting measures, and a debt-free balance sheet with share repurchases as evidence of its commitment to shareholder value. An analyst has a Hold rating on OSUR stock with a $3.00 price target, while TipRanks' AI Analyst Spark rates OSUR as Neutral due to past financial underperformance balanced by signs of stabilization and a promising product pipeline.

OraSure Technologies Inc (OSUR) is currently undervalued, with a fair price estimated between $3.45 and $5.32 compared to its current price of $3.00. While its current P/S ratio of 1.48 is considered undervalued relative to its five-year average, it is still 47.52% above the industry average, which the analysis suggests may be unsustainable given robust revenue growth of -28.53%. The article provides various valuation metrics and compares them to historical averages and industry benchmarks.